Protagonist Therapeutics Raises Price Target, Advances Pipeline

On Jan. 30 H.C. Wainwright raised its price target on Protagonist Therapeutics (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating, the firm said. In early February a company director sold 20,000 shares for about $1.7 million as Protagonist reported two potential late-stage assets — icotrokinra and rusfertide — with NDAs submitted in 2025 and multiple Phase 2/3 readouts expected, supported by J&J and Takeda partnerships.